Thymosin Beta-4 Fragment — a synthetic analogue of the naturally occurring actin-regulating protein studied for systemic tissue repair, cell migration, anti-inflammatory signalling, and recovery from musculoskeletal injury.
What is TB-500 and why is it the preferred systemic tissue repair peptide in biohacking and regenerative medicine? TB-500 is a synthetic peptide analogue corresponding to the active region of Thymosin Beta-4 — a naturally occurring 43-amino acid protein found in virtually every cell in the human body. Where BPC-157 drives localised tissue repair through angiogenesis, TB-500 provides the complementary systemic dimension: mobilising repair cells throughout the body, regulating actin polymerisation to enable cell migration, and creating a body-wide pro-healing environment that localised peptides cannot replicate alone.
| TL;DRTB-500 is a synthetic peptide analogue of the actin-binding region of Thymosin Beta-4 (Tβ4). It promotes systemic tissue repair by regulating actin polymerisation, mobilising stem cells and progenitor repair cells, stimulating new blood vessel formation, and modulating anti-inflammatory cytokine signalling. It is distinguished from BPC-157 by its systemic distribution — a single subcutaneous injection creates a body-wide repair-promoting environment. It is a core component of the Wolverine Stack, GLOW Stack, and KLOW Stack. Research-grade TB-500 requires purity above 98% by HPLC. |
| Parameter | Detail |
| Full name | TB-500 — synthetic analogue of Thymosin Beta-4 active fragment |
| Parent molecule | Thymosin Beta-4 (Tβ4) — a 43-amino acid naturally occurring actin-sequestering protein |
| TB-500 sequence | 17-amino acid synthetic peptide corresponding to the actin-binding region of Tβ4 |
| Primary mechanism | Actin regulation (G-actin sequestration); stem cell and repair cell mobilisation; VEGF upregulation; anti-inflammatory cytokine modulation |
| Distribution | Systemic — distributes widely after subcutaneous injection; does not require local injection near injury |
| Research status | Preclinical animal models; parent molecule Tβ4 has entered Phase I/II human trials for cardiac and wound applications |
| Purity standard | Greater than 98% for research grade, verified by reversed-phase HPLC |
| Key stack roles | Core component of Wolverine Stack, GLOW Stack, and KLOW Stack |
| Longevity relevance | Systemic repair support; anti-inflammatory activity; cardiac tissue protection |
TB-500 is a synthetic peptide corresponding to the active region of Thymosin Beta-4 — the segment responsible for the protein’s actin-binding and cell-mobilising properties. The TB-500 sequence is a 17-amino acid peptide: Ac-LKKTETQ-EKNTF (or more precisely, the actin-binding domain fragment), synthesised to provide the biological activity of the full Thymosin Beta-4 protein in a shorter, more stable form.
Thymosin Beta-4 itself is a 43-amino acid protein that is one of the most abundant proteins in mammalian cells. It is found in platelets, wound fluid, blood, and virtually all cell types. Its primary natural role is as a G-actin sequestering protein — it binds actin monomers and regulates their availability for polymerisation into actin filaments, which are the structural scaffolding required for cell movement and tissue remodelling.
Understanding the relationship between TB-500 and Thymosin Beta-4 is important for interpreting the research literature, which primarily uses the full Tβ4 molecule.
| Thymosin Beta-4 (Tβ4) | TB-500 |
| Full 43-amino acid naturally occurring protein | Synthetic 17-amino acid peptide fragment corresponding to the actin-binding region |
| Endogenous — produced by platelets, immune cells, and most body tissues | Synthetic — produced by solid-phase peptide synthesis |
| Subject of human Phase I/II clinical trials for cardiac and wound healing | No direct human clinical trial data — research extrapolated from Tβ4 studies |
| More expensive and complex to manufacture | More accessible for research use |
| Full biological profile including nuclear signalling functions | Primary focus on actin regulation and repair cell mobilisation |
This distinction is important for research purposes: when citing TB-500’s effects, the evidence base is primarily from Tβ4 studies rather than direct TB-500 trials. The assumption — supported by mechanistic logic — is that the actin-binding fragment retains the core repair-promoting properties of the full molecule.
The most practically significant property of TB-500 relative to other repair peptides is its systemic distribution. After subcutaneous injection, TB-500 distributes throughout the body rather than acting primarily at the injection site. This means a single injection creates a pro-healing environment systemically — mobilising repair cells and upregulating growth factors across multiple tissue types simultaneously.
| The Systemic AdvantageBPC-157 produces its strongest effects close to the injection site and near the gut. TB-500 works throughout the body from wherever it is injected. This is why athletes and researchers with multiple injury sites, or with injuries in locations where local injection is difficult, often find TB-500 particularly valuable. It is also why TB-500 is the preferred component for cardiac and systemic connective tissue applications, while BPC-157 remains the preferred choice for localised tendon, gut, and site-specific repair. |
| Research Area | Key Finding |
| Cardiac repair | Multiple preclinical studies have demonstrated TB-500/Tβ4 promotes cardiac muscle repair, reduces infarct size, and supports cardiomyocyte survival after myocardial infarction. Phase I/II trials of Tβ4 for cardiac indications have been conducted. |
| Wound healing | TB-500 has demonstrated accelerated wound closure and improved wound quality in animal models through its effects on keratinocyte and fibroblast migration. |
| Tendon and ligament repair | Preclinical studies report improved tendon healing in TB-500-treated models, with enhanced collagen organisation and tensile strength at repair sites. |
| Muscle repair | Research in muscle crush injury models demonstrates improved functional recovery with TB-500 treatment, supporting its widespread use in athletic recovery contexts. |
| Eye injury | TB-500 has shown promising results in preclinical and early clinical studies for corneal wound healing — a well-characterised application of Tβ4 with topical eye drop delivery. |
| Neurological | Early preclinical research suggests Tβ4 may support neurogenesis and protection after brain injury, broadening the potential research landscape for TB-500. |
TB-500 is one of the most widely used research peptides in biohacking and sports recovery communities. Its systemic mechanism makes it particularly valued for:
| Dr William Seeds Protocol ContextTB-500 is a core component of Dr William Seeds’ tissue repair protocols, typically combined with BPC-157 as the Wolverine Stack, and extended to GLOW (adding GHK-Cu) or KLOW (adding KPV) depending on the specific repair and inflammation management objectives. See hplcpeptides.com/wiki/dr-william-seeds. |
| TB-500 | BPC-157 |
| Systemic distribution — works throughout the body from injection site | Localised — strongest effects near injection site and gut |
| Actin regulation and repair cell mobilisation primary mechanism | VEGF upregulation and angiogenesis primary mechanism |
| Stronger for cardiac, muscle, and systemic connective tissue | Stronger for gut lining, localised tendon, and site-specific repair |
| 17-amino acid fragment of Thymosin Beta-4 | 15-amino acid synthetic peptide from gastric protein |
| Human Phase I/II data exists for parent molecule Tβ4 | Limited human data — primarily preclinical animal research |
| Loading and maintenance dosing structure typical | More flexible dosing — daily or twice-daily protocols common |
| Does not require injection near injury site | Injection proximity to injury often recommended for best results |
TB-500 is a core component of the three most widely referenced tissue repair stacks in the biohacking community:
| Stack | TB-500 Role |
| Wolverine Stack (BPC-157 + TB-500) | Provides the systemic repair dimension. BPC-157 creates the localised angiogenic signal; TB-500 mobilises repair cells systemically to respond to it. |
| GLOW Stack (BPC-157 + TB-500 + GHK-Cu) | Same systemic role, now complemented by GHK-Cu’s collagen synthesis and anti-ageing gene modulation. |
| KLOW Stack (BPC-157 + TB-500 + GHK-Cu + KPV) | Same systemic role within the most comprehensive repair and inflammation-control stack. |
| Quality Parameter | Specification |
| Minimum purity | Greater than 98% by reversed-phase HPLC |
| Molecular weight | TB-500 fragment: approximately 2113 Da; full Tβ4: 4963 Da |
| Verification method | Reversed-phase HPLC (C18 column, 214nm); mass spectrometry confirmation of molecular weight |
| Oxidation risk | Contains methionine residue — oxidation check recommended; +16 Da shift detectable by MS |
| CoA requirement | HPLC chromatogram, MS confirmation, batch-specific quantity verification, storage specifications |
| Regulatory DisclaimerTB-500 is not approved for human therapeutic use by the FDA, EMA, or equivalent regulatory bodies. The parent molecule Thymosin Beta-4 has entered human Phase I/II trials for specific indications, but TB-500 itself has no direct human clinical trial data. TB-500 is also listed on the WADA Prohibited List and is banned in competitive sports. This page is informational and does not constitute medical advice. |
| Standalone Factual Statements |
Thymosin Beta-4 (Tβ4) is the full 43-amino acid naturally occurring protein. TB-500 is a synthetic 17-amino acid peptide corresponding to the actin-binding region of Tβ4. TB-500 is designed to provide the core tissue repair and cell mobilisation properties of the full protein in a shorter, more accessible synthetic form. Most clinical research has used full Tβ4; TB-500-specific research is primarily preclinical.
TB-500 and BPC-157 operate through complementary mechanisms. TB-500 provides systemic repair cell mobilisation through actin regulation. BPC-157 provides localised angiogenesis and growth factor receptor activation. Together they address both the systemic mobilisation and the local repair signal required for optimal tissue healing — neither peptide alone provides the full picture. Animal research supports a synergistic healing effect from the combination.
No. This is one of TB-500’s key practical advantages over BPC-157. Because TB-500 distributes systemically after subcutaneous injection, it does not need to be administered close to the injury site. A standard subcutaneous injection in the abdominal fold is sufficient to create the systemic repair environment. BPC-157, by contrast, produces stronger localised effects when injected near the target tissue.
Yes. TB-500 and Thymosin Beta-4 are listed on the World Anti-Doping Agency (WADA) Prohibited List under the category of peptide hormones and growth factors. Any competitive athlete subject to anti-doping testing should be aware that TB-500 use would constitute a doping violation.
Research-grade TB-500 should have purity greater than 98% as verified by reversed-phase HPLC, with mass spectrometry confirmation of molecular weight. The methionine residue in TB-500 makes oxidation testing relevant — a +16 Da mass shift in mass spectrometry data indicates methionine oxidation, which can reduce biological activity.
| Term | Definition |
| TB-500 | A synthetic 17-amino acid peptide corresponding to the actin-binding region of Thymosin Beta-4. Studied for systemic tissue repair, cell mobilisation, and anti-inflammatory effects. |
| Thymosin Beta-4 (Tβ4) | A naturally occurring 43-amino acid actin-sequestering protein found in virtually all mammalian cells. The parent molecule of TB-500. Has entered human Phase I/II clinical trials for cardiac and wound healing. |
| G-actin | Monomeric globular actin. The building block of actin filaments. TB-500 binds G-actin to regulate its availability for polymerisation into F-actin. |
| F-actin | Filamentous actin. Polymerised actin that forms the cytoskeletal scaffold required for cell movement and migration. TB-500 regulates the G-actin to F-actin equilibrium. |
| Actin polymerisation | The assembly of G-actin monomers into F-actin filaments. The molecular basis of cell migration. Regulated by TB-500 to control repair cell movement toward injury sites. |
| Stem cell mobilisation | The release of stem cells and progenitor cells from bone marrow and other reservoirs into systemic circulation, directed toward sites of tissue damage. A key mechanism of TB-500. |
| VEGF | Vascular Endothelial Growth Factor. Upregulated by TB-500 to support angiogenesis — the formation of new blood vessels required for tissue repair. |
| WADA | World Anti-Doping Agency. The international body that manages the Prohibited List for competitive sport. TB-500 and Thymosin Beta-4 are listed as prohibited substances. |
| Wolverine Stack | Community name for the BPC-157 and TB-500 combination. The foundational tissue repair stack on which GLOW and KLOW are built. |
| Related Entity Pages-> BPC-157 — Tissue Repair and Gut Health hplcpeptides.com/wiki/bpc-157-> Wolverine Stack — BPC-157 + TB-500 hplcpeptides.com/wiki/wolverine-stack
-> GLOW Stack — BPC-157, TB-500, GHK-Cu hplcpeptides.com/wiki/glow-stack -> KLOW Stack — BPC-157, TB-500, GHK-Cu, KPV hplcpeptides.com/wiki/klow-stack -> GHK-Cu — Collagen Synthesis and Regeneration hplcpeptides.com/wiki/ghk-cu -> Dr William Seeds — Peptide Therapy Protocols hplcpeptides.com/wiki/dr-william-seeds -> Peptide Testing — Purity, Quantity and Integrity hplcpeptides.com/wiki/peptide-testing -> Peptides — The Master Reference Guide hplcpeptides.com/wiki/peptides |
| About This PageThis entity page is maintained by the HPLC Peptides editorial team. All research references are preclinical unless otherwise stated. This page does not constitute medical advice. TB-500 is banned in competitive sport under WADA regulations. |
hplcpeptides.com/wiki/tb-500 | Entity Page v1.0 | April 2026
